Speakers

Expand/Collapse

Andrew Lim
Chief Executive Officer
Circumvent Pharmaceuticals

Beth Hoffman
Founder, President & CEO
Origami Therapeutics

Charlotte Teunissen
Professor Neurochemistry
VUmc

Daniel Lorrain
CSO
Pipeline Therapeutics

Dimitry Ofengeim
Precision Neurology and Neuroinflammation Head
Sanofi

Don W Cleveland
Chair, Distinguished Professor of Cellular & Molecular Medicine & Neurosciences Member
Ludwig Institute for Cancer Research

Elena H Martínez-Lapiscina
Rare Neurological Disorders Lead - Clinical Neurologist
European Medicines Agency

Gene Liau
Executive Vice President; Head Research & Preclinical Development
Stoke Therapeutics

Gennaro Pagano
Expert Medical Director, Group Leader in Early Development, and Chair of Medical Directors Fellowship
Roche Pharma and Early Development (pRED)

Henrik Zetterberg
Professor
University of Gothenburg

Howard Federoff
Chief Executive Officer
Aspen Neuroscience

Isaac Veinbergs
President & CEO
Libra Therapeutics

Day One

9:00 am | Chair’s Opening Remarks

Day Two

9:00 am | Chair’s Opening Remarks

Janna Hutz
Head of Discovery Data Science
Eisai Center for Genetics Guided Dementia Discovery (G2D2)

Jeff Dage
Senior Research Advisor
Eli Lilly & Company

Jonathan Behr
Partner
Dementia Discovery Fund

Day Two

9:10 am | Driving Investment in Neurodegeneration

Jonathan Levenson
Vice President of Translational Biology
Tiaki Therapeutics

José Luis Molinuevo
VP Clinical Development, Neurodegeneration
Lundbeck

Judith Kelleher-Andersson
President and CEO
Neuronascent

Krystof Bankiewicz
President & Chief Executive Officer, CEO
Brain Neurotherapy Bio, Columbus Children’s Foundation

Larry Brown
Executive Vice President & Chief Scientific Officer
Noveome Biotherapeutics

Mark Treherne
Chairman
Gen2 Neuroscience

Martin Tolar
Founder, President & CEO
Alzheon

Day One

3:00 pm | ALZ-801 Phase 3 Program: A Targeted Oral Disease Modifying Therapy for Alzheimer’s Disease

4:00 pm | Live Q&A With Your Expert Speakers

Maurice Zauderer
President & CEO
Vaccinex

Michael Kurnellas
Staff Scientist
Alector

Day One

3:30 pm | Clinical Case Study: Exploring AL001 for the Treatment of FTD

4:00 pm | Live Q&A With Your Expert Speakers

Michele Vendruscolo
Professor & CSO
Cambridge University Centre for Misfolding Diseases & Wren Therapeutics

Day One

2:30 pm | Targeting Amyloid Beta for Alzheimer’s Disease

4:00 pm | Live Q&A With Your Expert Speakers

Michelle Hastings
Director, Center for Genetic Diseases, Professor
Chicago Medical School, RFUMS

Neil Cashman
CSO of ProMIS Neurosciences, Professor, Neurology
University of British Columbia

Robert Rissman
Professor
UC San Diego

Sabrina Paganoni
Assistant Professor
Harvard Medical School

Sanjay Kakkar
President & CEO
Tranquis Therapeutics

Day One

2:00 pm | Targeting Myeloid Immune Cell Dysfunction to Revolutionize Neurodegenerative Treatment – From Discovery to the Clinic

4:00 pm | Live Q&A With Your Expert Speakers

Selina Wray

Vanessa Almendro
Head of Strategy & Operations
Eisai Center for Genetics Guided Dementia Discovery (G2D2)